Literature DB >> 34188042

Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.

Yue Lu1, Alphonsus H C Ng1, Frances E Chow2, Richard G Everson2, Beth A Helmink3, Michael T Tetzlaff3, Rohit Thakur3, Jennifer A Wargo3, Timothy F Cloughesy2, Robert M Prins2, James R Heath4.   

Abstract

The response of patients with recurrent glioblastoma multiforme to neoadjuvant immune checkpoint blockade has been challenging to interpret due to the inter-patient and intra-tumor heterogeneity. We report on a comparative analysis of tumor tissues collected from patients with recurrent glioblastoma and high-risk melanoma, both treated with neoadjuvant checkpoint blockade. We develop a framework that uses multiplex spatial protein profiling, machine learning-based image analysis, and data-driven computational models to investigate the pathophysiological and molecular factors within the tumor microenvironment that influence treatment response. Using melanoma to guide the interpretation of glioblastoma analyses, we interrogate the protein expression in microscopic compartments of tumors, and determine the correlates of cytotoxic CD8+ T cells, tumor growth, treatment response, and immune cell-cell interaction. This work reveals similarities shared between glioblastoma and melanoma, immunosuppressive factors that are unique to the glioblastoma microenvironment, and potential co-targets for enhancing the efficacy of neoadjuvant immune checkpoint blockade.

Entities:  

Year:  2021        PMID: 34188042     DOI: 10.1038/s41467-021-24293-4

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  41 in total

1.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

Authors:  Quinn T Ostrom; Haley Gittleman; Paul Farah; Annie Ondracek; Yanwen Chen; Yingli Wolinsky; Nancy E Stroup; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2013-11       Impact factor: 12.300

2.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Authors:  Junfei Zhao; Andrew X Chen; Robyn D Gartrell; Andrew M Silverman; Luis Aparicio; Tim Chu; Darius Bordbar; David Shan; Jorge Samanamud; Aayushi Mahajan; Ioan Filip; Rose Orenbuch; Morgan Goetz; Jonathan T Yamaguchi; Michael Cloney; Craig Horbinski; Rimas V Lukas; Jeffrey Raizer; Ali I Rae; Jinzhou Yuan; Peter Canoll; Jeffrey N Bruce; Yvonne M Saenger; Peter Sims; Fabio M Iwamoto; Adam M Sonabend; Raul Rabadan
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

Review 4.  The Microenvironmental Landscape of Brain Tumors.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

5.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

6.  Glycerolipid biosynthesis in rat adipose tissue. 11. Effects of polyamines on Mg2+-dependent phosphatidate phosphohydrolase.

Authors:  S C Jamdar; L J Osborne
Journal:  Biochim Biophys Acta       Date:  1983-06-16

7.  Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson
Journal:  CA Cancer J Clin       Date:  2017-10-13       Impact factor: 508.702

8.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

9.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.

Authors:  David A Reardon; Alba A Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

10.  Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Authors:  Rodabe N Amaria; Sangeetha M Reddy; Hussein A Tawbi; Michael A Davies; Merrick I Ross; Isabella C Glitza; Janice N Cormier; Carol Lewis; Wen-Jen Hwu; Ehab Hanna; Adi Diab; Michael K Wong; Richard Royal; Neil Gross; Randal Weber; Stephen Y Lai; Richard Ehlers; Jorge Blando; Denái R Milton; Scott Woodman; Robin Kageyama; Daniel K Wells; Patrick Hwu; Sapna P Patel; Anthony Lucci; Amy Hessel; Jeffrey E Lee; Jeffrey Gershenwald; Lauren Simpson; Elizabeth M Burton; Liberty Posada; Lauren Haydu; Linghua Wang; Shaojun Zhang; Alexander J Lazar; Courtney W Hudgens; Vancheswaran Gopalakrishnan; Alexandre Reuben; Miles C Andrews; Christine N Spencer; Victor Prieto; Padmanee Sharma; James Allison; Michael T Tetzlaff; Jennifer A Wargo
Journal:  Nat Med       Date:  2018-10-08       Impact factor: 53.440

View more
  7 in total

Review 1.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

2.  The future of cancer immunotherapy for brain tumors: a collaborative workshop.

Authors:  Christine E Brown; Samantha Bucktrout; Lisa H Butterfield; Olga Futer; Evanthia Galanis; Adilia Hormigo; Michael Lim; Hideho Okada; Robert Prins; Sara Siebel Marr; Kirk Tanner
Journal:  J Transl Med       Date:  2022-05-23       Impact factor: 8.440

3.  Construction and Validation of a 6-Ferroptosis Related Gene Signature for Prognosis and Immune Landscape Prediction in Melanoma.

Authors:  Zhanghui Yue; Jianfang Sun; Liqing Shi
Journal:  Front Genet       Date:  2022-05-25       Impact factor: 4.772

Review 4.  The Advances in Glioblastoma On-a-Chip for Therapy Approaches.

Authors:  Arielly H Alves; Mariana P Nucci; Javier B Mamani; Nicole M E Valle; Eduarda F Ribeiro; Gabriel N A Rego; Fernando A Oliveira; Matheus H Theinel; Ricardo S Santos; Lionel F Gamarra
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

5.  Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression.

Authors:  Hinda Najem; Martina Ott; Cynthia Kassab; Arvind Rao; Ganesh Rao; Anantha Marisetty; Adam M Sonabend; Craig Horbinski; Roel Verhaak; Anand Shankar; Santhoshi N Krishnan; Frederick S Varn; Víctor A Arrieta; Pravesh Gupta; Sherise D Ferguson; Jason T Huse; Gregory N Fuller; James P Long; Daniel E Winkowski; Ben A Freiberg; Charles David James; Leonidas C Platanias; Maciej S Lesniak; Jared K Burks; Amy B Heimberger
Journal:  JCI Insight       Date:  2022-05-09

Review 6.  The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.

Authors:  Víctor A Arrieta; Hinda Najem; Edgar Petrosyan; Catalina Lee-Chang; Peiwen Chen; Adam M Sonabend; Amy B Heimberger
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923

Review 7.  Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches.

Authors:  Elena Anghileri; Monica Patanè; Natalia Di Ianni; Irene Sambruni; Martina Maffezzini; Micaela Milani; Luisa Maddaloni; Bianca Pollo; Marica Eoli; Serena Pellegatta
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.